1. Furchgott R.F., Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
2. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endotheUum-derived relaxing factor Nature 1987; 327: 524-6.
3. Ignarro L.J., Wei Lun. Visiting Professional Lecture: Nitric oxide in the regulation of vascular function: an historical overview. J Card Surg 2002; 17 (4): 301-6.
4. Dzau V.J., Gibbons G.H. Endothelium and growth factor in vascular remodeling in Hypertension. Hypertension 1991; 18(Suppl. Ill): 115-21.
5. Maffei A., Vecchione C., Aretini A., et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 2006; 19(6): 579-86.
6. Ritter J.M. Nebivolol: endotheUum-mediated vasodilating effect. J Cardiovasc Pharmacol 2001; 38(Suppl 3): S13-6.
7. Ignarro L.J. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker Blood Press Suppl 2004; 1:2-16.
8. Dessy C., Saliez J. Ghisdal P., et al. Endothelial beta-3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112(8): 1198-205.
9. Garban H.J., Buga G.M., Ignarro L.J. Estrogen-receptor mediated vascular responsiveness to nebivolol: a novel endothehum-related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 2004; 43(5): 638-44.
10. Kalinowski L., Dobrucki L.W., Szczepanska-Konkel M., et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107(21): 2747-52.
11. Brehm B.R., Wolf S.C., Bertsch D., et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49(2): 430-9.
12. Coats A.J.C. SENIORS: Study of Effects of Nebivolol Intervention on Outcomes and RehospitaUzation in Seniors with heart failure. Program and abstracts from the European Society of Cardiology Congress 2004; August 28 -September 1, 2004; Munich, Germany.
13. Ghio S., Magrini G., Serio A., et al. Effects of nebivolol in elderly heart failure with and without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur HeartJ 2006; 27(5): 562-8.
14. Edes I., Gasior Z., Wta K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study Eur J Heart Fail 2005; 7(4): 631-9.
15. Evdokimova A.G., Radzevich A.E., Tereshchenko O.I., Kovalenko E.V. Otsenka klinicheskoi effektivnosti vklyucheniya nebivolola i metoprolola v kompleksnuyu terapiyu bol'nykh ishemicheskoi bolezn'yu serdtsa s khronicheskoi serdechnoi nedostatochnost'yu II-III funktsional'nykh klassov. Kardiovask ter profil 2005; 4(2): 52-9. effektom ne okazyval ugnetayushchego deistviya na seksual'nuyu funktsiyu [36]. V zaklyuchenii sleduet otmetit', chto s kazhdym godom spektr real'nogo i potentsial'nogo primeneniya nebivolola rasshiryaetsya blagodarya ego vazodilatiruyushchim, antiokislitel'nym, neitral'nym metabolicheskim svoistvam i vysokoi kardioselektivnosti.
16. Makolkin V.I., Akhmedova O.O., Buval'tsev V.I. i dr. Klinicheskie i metabolicheskie effekty kardioselektivnykh beta-adrenoblokatorov nebivolola i metoprolola u bol'nykh arterial'noi gipertenziei i ishemicheskoi bolezn'yu serdtsa, sochetayushcheisya s sakharnym diabetom 2 tipa. Kardiologiya 2003; 43(2): 40-3.
17. Makolkin V.I., Sulimov V.A., Tavrilov Yu.V. i dr. Otsenka effektivnosti i bezopasnosti nebivolola u patsientov so stabil'noi stenokardiei napryazheniya. Kardiologiya 2002; 42(2): 24-7.
18. Van Nueten L. Overview of therapeutic efficacy and safety of nebivolol in the treatment of hypertension. JRF Clinical Research Report on R67555. December 1994.
19. Von FaUois J., FauUiaber H.D. Nebivolol, a beta-blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study. Schweiz Rundsch Med Prax 2001; 90(11): 435-41.
20. Van Nueten L., Lacourciere Y., Vyssoulis G., et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 1998; 5(4): 237-43.
21. Van Nueten L., ScheHing A., Vertommen C., et al. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind, randomized, comparative trial. J Human Hypertens 1997; 11(12): 813-9.
22. Elezer M.L., Boiko H.B., Abil'dinova A.Zh., Sobolev K.E. Sravnitel'naya effektivnost' lecheniya nebivololom i bisoprololom bol'nykh arterial'noi gipertenziei. Kardiovask ter profil 2004; 3(5):43-50.
23. Brett S.E., Forte R., Chowienczyk P.J., et al. Comparison of the effects of nebivolol and bisoprolol on systematic vascular resistance in patients with essential hypertension. CUn Drug Invest 2002; 22(6): 355-9.
24. Buval'tsev V.I., Spasskaya M.B., Nebieridze D.V. i dr. Farmakologicheskaya modulyatsiya sinteza N0 u patsientov s arterial'noi gipertenziei i endotelial'noi disfunktsiei. Klinmed 2003; 81(7): 51-5.
25. Fratta Passini A., Garbin U., Nava M.S., et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23(3): 589-96.
26. Nodari S., Metra M., Dei Cas L. Beta-blocker treatment of the patients with diastolic heart failure and arterial hypertension. A prospective, randomized comparison of the long-term effects of atenolol versus nebivolol. Eur J Heart Fail 2003; 5: 621-7.
27. Easterling T.R., Brateng D., Schmuker B., et al. Prevention of preeclampsia: a randomized trial of atenolol in hyperdinamic patients before onset of hypertension. Obstet Gynecol 1999; 93: 725-33.
28. Von Dadelszen P., Ornstein M.P., Bull S.B., et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000; 355: 87-92.
29. Makolkin V.I. Vozmozhno li primenenie b-adrenoblokatorov pri arterial'noi gipertonii u bol'nykh metabolicheskim sindromom i sakharnym diabetom 2 tipa? RMZh (kardiologiya) 2005; 13(11): 3-6.
30. Dedov I.I., Bondarenko I.Z., Solyanik Yu.A., Aleksandrov An.A. Metabolicheskie effekty nebivolola u bol'nykh insulinnezavisimym sakharnym diabetom. Kardiologiya 2001; 5: 35-7.
31. Peter R., Martin U., Sharma A., Dunne F. Effect of treatment with nebivolol on parameters of oxydative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther 2006; 31(2): 153-9.
32. Kaiser T., Heise T., Nosek L., et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006; 24(7): 1397-403.
33. Ovcharenko S.I., Litvinova I.V., Makolkin V.I. Primenenie superselektivnogo beta-adrenoblokatora nebivolola u patsientov s serdechno-sosudistoi patologiei v sochetanii s bronkhoobstruktivnym sindromom. RKZh 2006; 2(58): 78-82.
34. Matthys H., Giebelhaus V., Von Fallois J. Nebivolol (nebilet) a beta-blocker of the third generation -also for patients with obstructive lung diseases? Z Kardiol 2001; 90(10): 760-5.
35. Boydak B., Nalbantgil S., Fici F., et al. A randomized comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Invest 2005; 25(6): 409-15.
36. Nebieridze D.V. Klinicheskoe znachenie disfunktsii endoteliya pri arterial'noi gipertonii. Consilium medicum 2005; (Pril. 1): 3-6.
37. Karpov Yu.A., Shubina A.T. Primenenie b-blokatorov v lechenii bol'nykh arterial'noi gipertoniei: novye vozmozhnosti i perspektivy. RMZh (kardiologiya) 2005; 13(19): 3-7.
Email this article 
